BBRP 11041
Alternative Names: BBRP-11041Latest Information Update: 26 Apr 2023
At a glance
- Originator BenoBio
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 13 Apr 2023 Preclinical trials in Osteoarthritis in South Korea, prior to April 2023 (unspecified route) (Beno Bio pipeline, April 2023)
- 13 Apr 2023 Beno Bio plans a phase I trial for osteoarthritis in 2024-2025 (Beno Bio pipeline, April 2023)
- 31 Dec 2020 Early research in Osteoarthritis in South Korea, prior to December 2020 (unspecified route) (Beno Bio pipeline, April 2023)